What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature built on Fundamental Research Corp's institutional-grade valuation methodology. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is TC Biopharm (Holdings) Plc stock price today?

TC Biopharm (Holdings) Plc (TCBPW) is currently trading at $0.006 USD on NASDAQ. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

How do I analyze TC Biopharm (Holdings) Plc stock performance?

Our Snowflake Analysis provides a visual snapshot of TC Biopharm (Holdings) Plc performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find TC Biopharm (Holdings) Plc financial statements?

Access TC Biopharm (Holdings) Plc complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC applies its proprietary valuation model to public stock analysis, so fair value estimates rest on a rigorous, data-driven methodology rather than a consensus average. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About TC Biopharm (Holdings) Plc

Industry

Biotechnology

Sector

Healthcare

CEO

Bryan Leland Kobel

Headquarters

Maxim 1, Motherwell, GB

Industry

Biotechnology

Sector

Healthcare

CEO

Bryan Leland Kobel

Headquarters

Maxim 1, Motherwell, GB

Description

TC Biopharm (Holdings) Plc is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing immunotherapy treatments. Their core approach revolves around an innovative allogeneic gamma delta T cell platform. The company's development portfolio features OmnImmune, an unmodified cell therapy designed to treat acute myeloid leukemia, and ImmuniStim, another unmodified cell therapy undergoing development for COVID-19. Additionally, they are working on TCB009, which targets gastrointestinal tract cancers. Further along, TCB005 and TCB006 are preclinical-stage allogeneic co-stimulatory GD-T CAR candidates intended to address various types of solid tumors. This company was established in 2013 and operates from its headquarters in Motherwell, United Kingdom.

TC Biopharm (Holdings) Plc

TCBPW•NASDAQ

TC Biopharm (Holdings) Plc

TCBPW•NASDAQ

Market cap

$602.60K

Sentiment

Your view on TCBPW

Mkt Cap

$602.60K

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About TC Biopharm (Holdings) Plc

Industry: Biotechnology
Sector: Healthcare
CEO: Bryan Leland Kobel
Headquarters: Maxim 1, Motherwell, GB

Industry: Biotechnology
Sector: Healthcare
CEO: Bryan Leland Kobel
Headquarters: Maxim 1, Motherwell, GB

Description

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for TC Biopharm (Holdings) Plc, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for TC Biopharm (Holdings) Plc. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for TC Biopharm (Holdings) Plc. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for TC Biopharm (Holdings) Plc. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for TC Biopharm (Holdings) Plc. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

TC Biopharm (Holdings) Plc valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold TC Biopharm (Holdings) Plc, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by TC Biopharm (Holdings) Plc executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming TC Biopharm (Holdings) Plc. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming TC Biopharm (Holdings) Plc. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for TC Biopharm (Holdings) Plc. Press releases and market coverage, newest first.

News

Latest Market News